Nicotine Addiction and Gating Deficits in Schizophrenia
精神分裂症的尼古丁成瘾和门控缺陷
基本信息
- 批准号:6954611
- 负责人:
- 金额:$ 7.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2006-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Nicotine addiction is very common in the United States and is a major health concern. It is not yet known why some people have an increased susceptibility to become addicted to nicotine. Cigarette smoking is much more prevalent in both non-medicated and medicated patients with schizophrenia compared to the general population. The long-term goal of this research program is to examine factors contributing to this comorbidity, using a rodent model of schizophrenia. An animal model of schizophrenia that parallels the behavioral, neurochemical, and developmental aspects of schizophrenia is the neonatal ventral hippocampus lesion (NVHL) model. Some of the cognitive, negative, and positive symptoms of schizophrenia are observed in the NVHL model, including deficits in prepulse inhibition (PPI), an operational measure of sensory gating. Nicotine increases PPI in both humans and animals. PPI deficits have been observed in psychiatric as well as non-psychiatric subjects after abstaining from smoking. Therefore, an increased vulnerability to nicotine addiction may be related to deficits in PPI. The proposed studies will determine whether nicotine can improve disrupted PPI in the NVHL animal model of schizophrenia, analogous to the effects of cigarette smoking in human patients with schizophrenia. These studies will also determine whether NVHL rats exhibit an increased preference for nicotine compared to controls. Additional studies will assess the effect of bupropion, an antidepressant that is prescribed for smoking cessation, on PPI deficits and nicotine preference in the NVHL model of schizophrenia. Since heavy smoking is a common occurrence in patients with schizophrenia, a better understanding of the effect of nicotine in schizophrenic-like animal models may lead to the identification of neurobiological factors that influence the vulnerability to become addicted to nicotine and lead to the development of novel pharmacological approaches for smoking cessation and/or the treatment of schizophrenia.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DARCI M NIELSEN其他文献
DARCI M NIELSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
The role of antidepressants in central and peripheral myeloid HIV persistence and inflammation
抗抑郁药在中枢和外周髓系 HIV 持续存在和炎症中的作用
- 批准号:
10762810 - 财政年份:2023
- 资助金额:
$ 7.75万 - 项目类别:
Association of genetic variation near the dopamine D2 receptor gene and other polymorphisms that modulate dopaminergic and opioid signaling on the weight loss response to naltrexone/bupropion
多巴胺 D2 受体基因附近的遗传变异与调节多巴胺能和阿片类信号传导对纳曲酮/安非他酮减肥反应的其他多态性的关联
- 批准号:
10586181 - 财政年份:2023
- 资助金额:
$ 7.75万 - 项目类别:
Short-term Outcome of Stimulant Use Disorder Treatment Trials
兴奋剂使用障碍治疗试验的短期结果
- 批准号:
10671072 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10437438 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10578721 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
Short-term Outcome of Stimulant Use Disorder Treatment Trials
兴奋剂使用障碍治疗试验的短期结果
- 批准号:
10462826 - 财政年份:2022
- 资助金额:
$ 7.75万 - 项目类别:
The Ohio Valley Node of the Clinical Trials Network
临床试验网络俄亥俄谷节点
- 批准号:
10441828 - 财政年份:2021
- 资助金额:
$ 7.75万 - 项目类别:
Behavioral and Pharmacological Treatments to Enhance Weight Outcomes after Metabolic and Bariatric Surgery
行为和药物治疗可增强代谢和减肥手术后的体重结果
- 批准号:
10653069 - 财政年份:2021
- 资助金额:
$ 7.75万 - 项目类别:














{{item.name}}会员




